Austin Younger, MD
Urology · Mobile, ALNPI 1992068183
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 50.7% of the total. Reporting peaked in 2022 at $6,923 and has fallen 99.5% since, to $37 in 2025. Among urology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $123.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Olympus America Inc.$5K
- Medtronic$1K
- Teleflex LLC$847
- Boston Scientific$309
- AbbVie$243
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$3,70021%
- Travel & lodging$1,1376%
- Food & beverage$4,07623%
- Education$9,00050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $9,079 |
| Olympus America Inc. | 15 | $4,628 |
| Medtronic(2 entities) | 36 | $1,198 |
| Teleflex LLC | 6 | $847 |
| Boston Scientific | 3 | $309 |
| AbbVie(2 entities) | 15 | $243 |
| Antares Pharma, Inc. | 4 | $185 |
| Johnson & Johnson | 10 | $155 |
| Neotract Inc. | 1 | $130 |
| Endo Pharmaceuticals Inc. | 6 | $124 |
| KARL Storz Endoscopy-america | 1 | $112 |
| Baxter Healthcare | 1 | $111 |
| Sumitomo Pharma America, Inc. | 5 | $86 |
| Dendreon Pharmaceuticals LLC | 2 | $77 |
| Myriad Genetic Laboratories, Inc. | 5 | $76 |
| Myovant Sciences Inc. | 5 | $73 |
| Urogen Pharma, Inc. | 4 | $61 |
| ABC Home Medical Supply, Inc. | 4 | $52 |
| Procept Biorobotics Corporation | 1 | $47 |
| Astellas Pharma US Inc | 3 | $46 |
| Urovant Sciences Inc | 2 | $35 |
| Accord Healthcare, Inc. | 2 | $35 |
| 180 Medical, Inc. | 1 | $27 |
| Coloplast | 1 | $27 |
| Endo USA, Inc. | 1 | $24 |
| BD | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $17 |
| Ambu Inc. | 1 | $15 |
| Telix Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$6,000
- iTIND System$4,373
- Da Vinci Surgical System$3,000
- UroLift System$776
- AMS 700 CXR RTE KIT$146
- UroLift$130
- INTERSTIM$120
- N/A$112
- FLOSEAL$111
How this compares
$17,913 in reported general payments places this provider in the 90th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 70 | $39,585 |
| GemtesaVibegron | 15 | $6,894 |
| Solifenacin Succinate | 31 | $1,657 |
| Tamsulosin Hcl | 138 | $1,558 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,112 |
| Testosterone Cypionate | 34 | $886 |
| Trospium Chloride | 13 | $733 |
| Finasteride | 43 | $343 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $276 |
| Levofloxacin | 20 | $42 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $46 | $39,58570 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $86 | $6,89415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Zachary ReardonMobile$19K
- Ted KleinMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
- Thomas ColemanMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.